|
1
|
Zhang DY, Yuan XQ, Yan H, Cao S, Zhang W,
Li XL, Zeng H and Chen XP: Association between DCK 35708 T>C
variation and clinical outcomes of acute myeloid leukemia in South
Chinese patients. Pharmacogenomics. 17:1519–1531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Betz BL and Hess JL: Acute myeloid
leukemia diagnosis in the 21st century. Arch Pathol Lab Med.
134:1427–1433. 2010.PubMed/NCBI
|
|
3
|
Creutzig U, van den Heuvel-Eibrink MM,
Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H,
Johnston D, Kinoshita A, et al: Diagnosis and management of acute
myeloid leukemia in children and adolescents: Recommendations from
an international expert panel. Blood. 120:3187–3205. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schrappe M, Hunger SP, Pui CH, Saha V,
Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluys AB, et
al: Outcomes after induction failure in childhood acute
lymphoblastic leukemia. N Engl J Med. 366:1371–1381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang M, Zeng P, Kang R, Yu Y, Yang L, Tang
D and Cao L: S100A8 contributes to drug resistance by promoting
autophagy in leukemia cells. PLoS One. 9:e972422014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang H, Zheng QL, Fang P, Zhang J, Zhang
T, Liu W, Guo M, Robinson CL, Chen SB, Chen XP, et al: Targeting
the PI3K/AKT pathway via GLI1 inhibition enhanced the drug
sensitivity of acute myeloid leukemia cells. Sci Rep. 7:403612017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kauko O, Imanishi S, Kulesskiy E, Laajala
TD, Yetukuri L, Padzik A, Jumppanen M, Haapaniemi P, Yadaw B, Suni
V, et al: Abstract 5560: Systemic map of protein phosphatase 2A
(PP2A)-regulated phosphotargets and drug responses in cancer cells.
Cancer Res. 77:55602017.
|
|
8
|
Mody HR, Hung SW, Naidu K, Lee H, Gilbert
CA, Hoang TT, Pathak RK, Manoharan R, Muruganandan S and
Govindarajan R: SET contributes to the epithelial-mesenchymal
transition of pancreatic cancer. Oncotarget. 8:67966–67979. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu M, Yu G, Yan T, Ke D, Wang Q, Liu R,
Wang JZ, Zhang B, Chen D and Wang X: Phosphorylation of SET
mediates apoptosis via P53 hyperactivation and NM23-H1 nuclear
import. Neurobiol Aging. 69:38–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Trotta R, Ciarlariello D, Dal Col J, Mao
H, Chen L, Briercheck E, Yu JH, Zhang JY, Perrotti D and Caligiuri
MA: The PP2A inhibitor SET regulates granzyme B expression in human
natural killer cells. Blood. 117:2378–2384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang
Z, Lu M, Wang C and He Z: Overexpression of PP2A inhibitor SET
oncoprotein is associated with tumor progression and poor prognosis
in human non-small cell lung cancer. Oncotarget. 6:14913–14925.
2015.PubMed/NCBI
|
|
12
|
Liu Y, He P, Liu F, Zhou N, Cheng X, Shi
L, Zhu H, Zhao J, Wang Y and Zhang M: Tetra-arsenic tetra-sulfide
(As4S 4) promotes apoptosis in retinoid acid-resistant human acute
promyelocytic leukemic NB4-R1 cells through downregulation of SET
protein. Tumour Biol. 35:3421–3430. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sultan C, Deregnaucourt J, Ko YW, Imbert
M, D'Agay MF, Gouault-Heilmann M and Brun B: Distribution of 250
cases of acute myeloid leukaemia (AML) according to the FAB
classification and response to therapy. Br J Haematol. 47:545–551.
1981. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He P, Liu Y, Qi J, Zhu H, Wang Y, Zhao J,
Cheng X, Wang C and Zhang M: Prohibitin promotes apoptosis of
promyelocytic leukemia induced by arsenic sulfide. Int J Oncol.
47:2286–2295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Y, He P, Liu F, Cheng X and Zhang M:
Influence of I2PP2A gene silencing by RNA interference on
proliferation and apoptosis of human acute promyelocytic leukemia
cell line NB4-R1. Zhonghua Xue Ye Xue Za Zhi. 35:732–736. 2014.(In
Chinese). PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun QY, Ding LW, Tan KT, Chien W,
Mayakonda A, Lin DC, Loh XY, Xiao JF, Meggendorfer M, Alpermann T,
et al: Ordering of mutations in acute myeloid leukemia with partial
tandem duplication of MLL (MLL-PTD). Leukemia. 31:1–10. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Y, Ma RH, Li XC, Zhang JY, Shi HR,
Wei W, Luo DJ, Wang Q, Wang JZ and Liu GP: Silencing I2PP2A rescues
tau pathologies and memory deficits through rescuing PP2A and
inhibiting GSK-3β signaling in human tau transgenic mice. Front
Aging Neurosci. 6:1232014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Sousa RT, Zanetti MV, Talib LL, Serpa
MH, Chaim TM, Carvalho AF, Brunoni AR, Busatto GF, Gattaz WF and
Machado-Vieira R: Lithium increases platelet serine-9
phosphorylated GSK-3β levels in drug-free bipolar disorder during
depressive episodes. J Psychiatr Res. 62:78–83. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bayarkhangai B, Noureldin S, Yu L, Zhao N,
Gu Y, Xu H and Guo C: A comprehensive and perspective view of
oncoprotein SET in cancer. Cancer Med. 2018:(Epub ahead of
print).
|
|
21
|
Jiang SW, Xu S, Chen H, Liu J and Duan P:
Oncogenic role of SET/I2PP2A for gynecologic cancers. Curr Drug
Targets. 18:1152–1157. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Enjoji S, Yabe R, Fujiwara N, Tsuji S,
Vitek MP, Mizuno T, Nakagawa T, Usui T, Ohama T and Sato K: The
therapeutic effects of SET/I2PP2A inhibitors on canine melanoma. J
Vet Med Sci. 77:1451–1456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobral LM, Coletta RD, Alberici LC, Curti
C and Leopoldino AM: SET/I2PP2A overexpression induces phenotypic,
molecular, and metabolic alterations in an oral keratinocyte cell
line. FEBS J. 284:2774–2785. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herbert M and Toth A: How meiosis creates
the single-copy genome. Dev Cell. 40:3–4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou H, Luo W, Zeng C, Zhang Y, Wang L,
Yao W and Nie C: PP2A mediates apoptosis or autophagic cell death
in multiple myeloma cell lines. Oncotarget. 8:80770–80789.
2017.PubMed/NCBI
|
|
26
|
Lu Y, Lei S, Wang N, Lu P, Li W, Zheng J,
Giri PK, Lu H, Chen X, Zuo Z, et al: Protective effect of
minocycline against ketamine-induced injury in neural stem cell:
Involvement of PI3K/Akt and Gsk-3 beta pathway. Front Mol Neurosci.
9:1352016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ye Z, Xia P, Cheng ZG and Guo Q:
Neuroprotection induced by sevoflurane-delayed post-conditioning is
attributable to increased phosphorylation of mitochondrial GSK-3β
through the PI3K/Akt survival pathway. J Neurol Sci. 348:216–225.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu J, Liao Q, He H, Zhong D and Yin K:
TWIST interacts with β-catenin signaling on osteosarcoma cell
survival against cisplatin. Mol Carcinog. 53:440–446. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ougolkov AV, Bone ND, Fernandez-Zapico ME,
Kay NE and Billadeau DD: Inhibition of glycogen synthase kinase-3
activity leads to epigenetic silencing of nuclear factor kappaB
target genes and induction of apoptosis in chronic lymphocytic
leukemia B cells. Blood. 110:735–742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ban JO, Kwak DH, Oh JH, Park EJ, Cho MC,
Song HS, Song MJ, Han SB, Moon DC, Kang KW and Hong JT: Suppression
of NF-kappaB and GSK-3beta is involved in colon cancer cell growth
inhibition by the PPAR agonist troglitazone. Chem Biol Interact.
188:75–85. 2010. View Article : Google Scholar : PubMed/NCBI
|
